The Haleon share price in UK pounds is a topic of interest for many investors. Haleon's market capitalization is around £45 billion, a significant figure in the pharmaceutical industry.
Haleon was spun off from GSK in 2022, and since then, its share price has been trading on the London Stock Exchange. Haleon's financial performance has been impacted by the global economic downturn.
In the first half of 2022, Haleon reported revenue of £5.3 billion, with a net loss of £1.3 billion.
For more insights, see: S B I Card Share Price
Haleon Share Price
The live share price of HALEON PLC is currently worth 3.79 GBP, which is a fraction of the company's value.
Owning a share of HALEON PLC means you possess a stake in the company, determined by the number of shares you own in relation to the total number of available shares.
The Haleon share price has retreated in the past few weeks, erasing some of the gains made earlier this year, and its London stock dropped to 375p, its lowest point since August 29.
This fluctuation in the share price is normal, as stock prices and information may change throughout the trading day.
You might like: What Are Stock Shares
Company News
Pfizer has significantly reduced its stake in Haleon, offloading shares worth $3.26 billion at 380 pence apiece, cutting its stake to 15%.
This major sale is a notable move in the world of consumer healthcare, with Pfizer now holding a smaller but still significant share of the company.
GSK, another major player in the industry, has also been making moves, raising $1.52 billion from selling its entire remaining stake in Haleon at a discount.
The British drugmaker plans to sell about 385 million shares, representing its entire shareholding, in the spun-off consumer healthcare business Haleon.
Haleon has been expanding its presence in the Chinese market, agreeing to raise its stake in a joint venture by 33% for 4.47 billion yuan ($637.35 million), taking its ownership to 88%.
Pfizer initially intended to offload about 5.9% of its stake in Haleon, selling around 540 million shares, but the exact details of the sale are not publicly disclosed.
In a separate development, GSK raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in Haleon.
Readers also liked: Buying and Trading Stocks
Financial Performance
As of February 1, 2025, the HLN.LON stock price stands at 3.79 GBP, representing a 0.3710% change from the previous close of 3.77 GBP.
Haleon's revenue in 2023 was 11.30 billion, an increase of 4.09% compared to the previous year's 10.86 billion.
The volume of shares traded yesterday was 7.25 million, indicating the level of market activity. This can give us an idea of the market's sentiment towards Haleon's stock.
Haleon's earnings in 2023 were 1.05 billion, a decrease of -1.04% compared to the previous year.
Explore further: Sentinel One Stock Symbol
Financial Performance
Haleon's revenue in 2023 was 11.30 billion, a 4.09% increase from the previous year's 10.86 billion.
The company's earnings were 1.05 billion in 2023, a decrease of -1.04% from the previous year.
Haleon's revenue took a marginal fall in its third-quarter, hurt by declines in its pain relief and digestive health segments.
The company has forecast high single-digit growth for its 2024 organic operating profit.
As of February 1, 2025, the stock price of HLN.LON stands at 3.79 GBP, with a 0.3710% change from the previous close of 3.77 GBP.
The volume of shares traded yesterday was 7256466, indicating the level of market activity.
Haleon's revenue missed market estimates in its first-quarter, due to retailer destocking in the U.S., and a cool down in demand for cold and flu medication after a strong first quarter last year.
The company's strong cash flows have been a notable aspect of its financial performance, with a net profit of 754M GBP.
Haleon's revenue was 11.30 billion in 2023, an increase of 4.09% compared to the previous year's 10.86 billion.
Intriguing read: Idfc First Bank Stock
Plc Holdings
Haleon PLC has a specific ISIN code, GB00BMX86B70, which is used to identify the company.
The company's holdings have been subject to various notifications, with the first one being on December 10, 2024, where the issuer details were disclosed.
The TR-1 standard form for notification of major holdings has been used in these notifications, indicating that the company's holdings have exceeded a certain threshold.
Haleon PLC has multiple notifications, with one being on December 11, 2024, where the issuer details and ISIN code were again disclosed.
The company's director or person with major responsibility (PDMR) shareholding has also been disclosed on December 11, 2024, with a public announcement made on the same day.
The most recent notification was made on December 13, 2024, with the issuer details and ISIN code being disclosed once more.
Readers also liked: Shiller Pe Ratio 2024
Analyst Insights
HLN stock has received a "Strong Buy" rating from 2 analysts, which is a promising sign for investors.
The average rating from these analysts suggests that they are optimistic about the stock's future performance.
According to their 12-month forecast, the stock price is expected to increase by 11.02% from the latest price, which is a significant growth opportunity.
This forecasted growth is based on a predicted stock price of $10.48, which is a specific target for investors to look out for.
Consider reading: Growth Equity Investing
Frequently Asked Questions
Is Haleon a buy or sell?
Haleon PLC is a Moderate Buy, with 8 analysts recommending a buy and 1 recommending a sell. However, its upside potential is 5.59% based on analysts' average price target.
What was the initial price of Haleon shares?
Haleon shares were initially priced at 330p per share. This marked the beginning of a volatile journey for the company's stock.
Featured Images: pexels.com
